**3.2 Aspirin**

There is some evidence that patients with NAFLD may benefit from taking aspirin daily. When 361 individuals with biopsy-proven NAFLD were recruited for a prospective cohort trial, those receiving daily aspirin treatment had a lower risk of developing NASH and fibrosis than those who did not get daily aspirin treatment [14]. Additionally, in a 3692-person trial, daily aspirin users were less likely to develop advanced fibrosis than non-users among 317 patients who did not have fibrosis at the time of recruitment. These results are very encouraging, and further research may provide evidence supporting aspirin's hepatoprotective properties [16].
